Suppression of tumour necrosis factor-α expression in leprosy skin lesions during treatment for leprosy

British Journal of Dermatology

Volumn 136, Issue 3, 1997, Pages 393-397

  Sugita, Y ^a   Miyamoto, M ^b   Koseki, M ^b   Ishii, N ^a   Nakajima, H ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b National Leprosarium Tama Zenshoen   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; OFLOXACIN; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CASE REPORT; HUMAN; HUMAN TISSUE; LEPROSY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031049104     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb14952.x     Document Type: Article

References (27)

1. Jopling WH, McDougall AC. Handbook of Leprosy, 4th edn. Oxford: Heinemann Medical, 1988.
2. Sugita Y. Leprosy. Clin Dermatol 1995; 13: 235-43.
3. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five group system. Int J Lepr 1966; 34: 255-73.
4. Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum faelor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
5. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630-2.
6. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28-31.
7. Arai K, Lee F, Miyajima A et al. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59: 783-836.
8. Pisa P, Gennene M, Soder O et al. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis 1990; 161: 988-91.
9. Sarno EN, Grau GE, Vieira LMM, Nevy JA. Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991; 84: 103-8.
10. Sullivan L, Sano S, Pirmez C et al. Expression of adhesion molecules in leprosy lesions. Infect Immun 1991; 59: 4154-60.
11. Silva CL, Foss NT. Tumor necrosis factor in leprosy patients. J Infect Dis 1989; 159: 787-90.
12. Barnes PF, Chatterjee D, Brennan PJ et al. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992; 60: 1441-6.
13. Ridley DS, Hilson GRF. A logarithmic index of bacilli in biopsies. Int J Lepr 1967; 35: 184-93
14. Grosset JH, Ji B, Guelpa-Lauras CC et al. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr 1990; 58: 281-95.
15. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277-9.
16. Nickoloff BJ, Karabin GD, Barker JNWN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991; 138: 129-40.
17. Piguet PF, Grau GE, Hauser C, Vassalli P. Tumor necrosis factor is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions. J Exp Med 1991; 173: 673-9.
18. Kindler V, Sappino AP, Grau GE et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
19. Bermudez LEM, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-γ, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140: 3006-13.
20. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Am Neurol 1988; 23: 339-46.
21. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors α and β induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987; 138: 775-9.
22. Bertolini DR, Nedwin GE, Bringman TS et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-18.
23. Yamamura M, Wang X-H, Ohmen JD et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992; 149: 1470-5.
24. Modlin RL, Mehra V, Jordan R et al. In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum. J Immunol 1986; 136: 883-6.
25. Sampaio EP, Moreira AL, Sarno EN et al. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-37.
26. Khanolkar-Young S, Rayment N, Brickell PM et al. Tumour necrosis factor-alpha (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995; 99: 196-202.
27. World Health Organization Study Group. Chemotherapy of leprosy for control programmes. Geneva: World Health Organization, 1982: Technical Report Series, no. 675.